UK-EU SPS Deal Threatens Novel Food Autonomy; Delays Cultivated Meat Investment

London, United Kingdom — 15 September 2026

A proposed UK-EU Sanitary and Phytosanitary (SPS) agreement threatens to bring Great Britain’s novel food authorisations under EU regulatory control, a move BeneMeat, a Czech cultivated meat technology company, warns could have wide-ranging implications beyond the food sector. The company asserts that this regulatory uncertainty is already impeding its UK commercial strategies, affecting critical investment and manufacturing expertise across the bioeconomy.

The agreement aims to streamline food and agricultural trade by aligning UK food safety, animal health, and plant health standards with EU rules. However, BeneMeat's primary concern is the potential loss of UK independence in authorising novel foods. In an open letter to the Prime Minister dated 8 September, BeneMeat urged the government to safeguard UK autonomy in biotechnology, arguing that cultivated meat development fosters capabilities applicable to medicine and advanced materials. This regulatory ambiguity has consequently put UK investment and partnership activities on hold, with preparatory work on product development and commercial deployment remaining under review.

BeneMeat has spent years evaluating how its cultivated cell lines could enter the UK market for both pet and human food applications. This involved preliminary product development and controlled tastings. However, potential food-industry partners require clear regulatory pathways and market entry timelines before committing significant resources to product development or local manufacturing capacity. With the regulatory pathway in flux, partners are deferring activities, slowing the transition from early development to commercial planning.

BeneMeat submitted its UK novel food application based on the existing UK regulatory framework, expecting assessment by the Food Standards Agency (FSA) under UK-specific requirements. Any shift in UK regulatory flexibility or alignment could alter the practical pathway, timing, and planning assumptions for pending applications. The company advocates for an explicit exemption for novel foods and biotechnology within any final SPS agreement to restore confidence for investment and partnerships, while maintaining robust food safety standards.

BeneMeat identifies significant potential for its cultivated meat in premium functional foods, noting its cultivated ingredient has already achieved regulatory recognition in the pet food sector. The novel food application for human consumption focuses on strengthening the nutritional profile of existing portfolios through functionalities such as purity and consistent batch quality. Looking ahead, the company aims to precisely customise nutritional parameters, such as optimising omega-3 to omega-6 ratios, to develop highly functional, tailored nutrition products.

What this means for United Kingdom

UK supplement brand owners and manufacturers must anticipate potential delays of 12-18 months for novel food ingredient approvals if the UK-EU SPS agreement limits independent FSA assessment. Procurement teams should diversify supply chains, reducing reliance on novel ingredients lacking clear UK regulatory timelines. Manufacturers considering cultivated protein integration will need to factor in increased R&D costs and extended reformulation windows due to this uncertainty. The UK risks losing its edge in advanced biotechnology, pushing IP and manufacturing investment towards more stable regulatory environments, potentially impacting domestic supply chain resilience and innovation in high-value nutritional products.

Many leading brands in this category are manufactured in partnership with Supplement Factory.